NCCN and ASCO guidelines support bisphosphonate use in multiple myeloma

National Comprehensive Cancer Network (NCCN) guidelines¹⁶

• Bisphosphonate therapy should be given to all patients with documented bone disease, including osteopenia

American Society of Clinical Oncology (ASCO) guidelines¹⁷

• Initiation of therapy
  • — ZOMETA (4 mg via 15-minute infusion) or pamidronate (90 mg via at least a 2-hour infusion) every 3 to 4 weeks is recommended for patients with evidence of osteolytic lesions
  • — For patients with pain secondary to bone metastases, ZOMETA or IV pamidronate should be administered as recommended above
• Duration of therapy
  • — Therapy should be continued for 2 years and thereafter at the discretion of the
    treating physician

ZOMETA is proven in clinical trials to reduce and delay SREs in multiple myeloma through 25 months⁶

---

Achieve maximum efficacy—treat with ZOMETA 4 mg every 3 to 4 weeks

---